EA201070496A1 - УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ - Google Patents

УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ

Info

Publication number
EA201070496A1
EA201070496A1 EA201070496A EA201070496A EA201070496A1 EA 201070496 A1 EA201070496 A1 EA 201070496A1 EA 201070496 A EA201070496 A EA 201070496A EA 201070496 A EA201070496 A EA 201070496A EA 201070496 A1 EA201070496 A1 EA 201070496A1
Authority
EA
Eurasian Patent Office
Prior art keywords
carbon
secretase modulators
compounds
formula
secretase
Prior art date
Application number
EA201070496A
Other languages
English (en)
Other versions
EA019710B1 (ru
Inventor
Чих Юнг Хо
Original Assignee
Янссен Фармацевтика, Н.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Янссен Фармацевтика, Н.В. filed Critical Янссен Фармацевтика, Н.В.
Publication of EA201070496A1 publication Critical patent/EA201070496A1/ru
Publication of EA019710B1 publication Critical patent/EA019710B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/76—Unsaturated compounds containing keto groups
    • C07C59/88—Unsaturated compounds containing keto groups containing halogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/57—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and carboxyl groups, other than cyano groups, bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/30—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings
    • C07C57/42—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
    • C07C57/52—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen
    • C07C57/58—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings
    • C07C57/60—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms containing halogen containing six-membered aromatic rings having unsaturation outside the rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C59/00—Compounds having carboxyl groups bound to acyclic carbon atoms and containing any of the groups OH, O—metal, —CHO, keto, ether, groups, groups, or groups
    • C07C59/40—Unsaturated compounds
    • C07C59/42—Unsaturated compounds containing hydroxy or O-metal groups
    • C07C59/56—Unsaturated compounds containing hydroxy or O-metal groups containing halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/61—Halogen atoms or nitro radicals

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Настоящее изобретение относится к соединениям с общей формулой (I), как показано ниже, определения А, X, R, R, R, R, R, R, Rи Rприведены в спецификации. Соединения с формулой (I) могут применяться для лечения заболеваний, связанных с активностью γ-секретазы, включая болезнь Альцгеймера.
EA201070496A 2007-10-19 2008-10-17 ПРОИЗВОДНЫЕ 2-АРИЛ-4-МЕТИЛПЕНТАНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ γ-СЕКРЕТАЗЫ EA019710B1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98120907P 2007-10-19 2007-10-19
PCT/US2008/080241 WO2009052334A1 (en) 2007-10-19 2008-10-17 Carbon linked modulators of y-secretase

Publications (2)

Publication Number Publication Date
EA201070496A1 true EA201070496A1 (ru) 2010-10-29
EA019710B1 EA019710B1 (ru) 2014-05-30

Family

ID=40338749

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201070496A EA019710B1 (ru) 2007-10-19 2008-10-17 ПРОИЗВОДНЫЕ 2-АРИЛ-4-МЕТИЛПЕНТАНОВОЙ КИСЛОТЫ В КАЧЕСТВЕ МОДУЛЯТОРОВ γ-СЕКРЕТАЗЫ

Country Status (17)

Country Link
US (1) US8692017B2 (ru)
EP (1) EP2215043B1 (ru)
JP (1) JP5417334B2 (ru)
KR (1) KR101618068B1 (ru)
CN (1) CN101896452B (ru)
AU (1) AU2008312355B2 (ru)
BR (1) BRPI0818773A2 (ru)
CA (1) CA2702959C (ru)
CO (1) CO6280527A2 (ru)
CR (1) CR11448A (ru)
EA (1) EA019710B1 (ru)
ES (1) ES2401833T3 (ru)
IL (1) IL205046A (ru)
MX (1) MX2010004310A (ru)
NI (1) NI201000065A (ru)
WO (1) WO2009052334A1 (ru)
ZA (1) ZA201003520B (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1799672B1 (en) * 2004-10-07 2013-01-02 Merck Sharp & Dohme Corp. Cgrp receptor antagonists
AU2008312612B2 (en) 2007-10-19 2013-11-28 Janssen Pharmaceutica, N.V. Piperidinyl and piperazinyl modulators of gamma-secretase
AU2008312355B2 (en) 2007-10-19 2013-07-04 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
WO2009052350A1 (en) 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Amine linked modulators of y-secretase
CN105801350B (zh) * 2016-04-29 2018-07-27 宜春学院 二芳基甲醇类化合物的合成方法

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790287A (fr) * 1971-10-28 1973-04-19 Delalande Sa Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
BE826017R (fr) * 1974-03-19 1975-08-26 Acides pyrimidin-6yl acethydroxamiques, leur procede de preparation et leur application en therapeutique
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
US5391817A (en) * 1993-12-21 1995-02-21 Bristol-Myers Squibb Biaryl phospholipase A2 inhibitors
US5877399A (en) 1994-01-27 1999-03-02 Johns Hopkins University Transgenic mice expressing APP-Swedish mutation develop progressive neurologic disease
AU5702201A (en) * 2000-04-13 2001-10-30 Mayo Foundation Abeta<sub>42</sub> lowering agents
DE10131899A1 (de) 2001-07-04 2003-02-27 Boehringer Ingelheim Pharma In vitro-Screening-Assay für gamma-Secretase
CN1829521B (zh) * 2003-06-16 2011-01-26 安纳考尔医药公司 耐水解的含硼治疗剂和使用方法
WO2006004555A1 (en) 2004-06-30 2006-01-12 Paysetter Pte Ltd System and method for facilitating transfer of physical money and/or credit
DE102004033876B4 (de) 2004-07-13 2009-01-15 Christoph Kaesbohrer Dreidimensionales Struktursystem
GB0416508D0 (en) * 2004-07-23 2004-08-25 Merck Sharp & Dohme Therapeutic agents
EP1650183A1 (en) 2004-10-21 2006-04-26 Cellzome Ag (Benzyloxy-biphenyl) acetic acids and derivatives thereof and their use in therapy
SI1849762T1 (sl) 2006-04-21 2009-12-31 Cellzome Ltd Substituirane bifenil karboksilne kisline in derivati le-teh
ATE445586T1 (de) 2006-04-21 2009-10-15 Cellzome Ltd Terphenylderivate zur alzheimerbehandlung
CA2654784A1 (en) * 2006-06-09 2007-12-13 Icos Corporation Substituted phenylacetic acids as dp-2 antagonists
EA200802417A1 (ru) 2006-06-09 2009-06-30 Икос Корпорейшн Замещенные фенилуксусные кислоты как dp-2-антагонисты
AU2008312771B2 (en) * 2007-10-17 2012-11-01 Janssen Pharmaceutica, N.V. Biphenyl carboxylic acids and derivatives thereof
AU2008312612B2 (en) * 2007-10-19 2013-11-28 Janssen Pharmaceutica, N.V. Piperidinyl and piperazinyl modulators of gamma-secretase
US7951843B2 (en) * 2007-10-19 2011-05-31 Janssen Pharmaceutica N.V. Amide linked modulators of γ-secretase
AU2008312355B2 (en) 2007-10-19 2013-07-04 Janssen Pharmaceutica, N.V. Carbon linked modulators of y-secretase
AU2008312362A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Gsm intermediates
WO2009052350A1 (en) * 2007-10-19 2009-04-23 Janssen Pharmaceutica, N.V. Amine linked modulators of y-secretase
US7968725B2 (en) 2008-07-22 2011-06-28 Janssen Pharmaceutica N.V. Pyridinyl modulators of γ-secretase

Also Published As

Publication number Publication date
CA2702959C (en) 2016-07-26
CN101896452B (zh) 2013-07-31
JP5417334B2 (ja) 2014-02-12
ES2401833T3 (es) 2013-04-24
CA2702959A1 (en) 2009-04-23
US8692017B2 (en) 2014-04-08
NI201000065A (es) 2010-09-13
MX2010004310A (es) 2010-05-03
EA019710B1 (ru) 2014-05-30
IL205046A0 (en) 2010-11-30
EP2215043A1 (en) 2010-08-11
AU2008312355A1 (en) 2009-04-23
US20090105288A1 (en) 2009-04-23
KR20100090688A (ko) 2010-08-16
CO6280527A2 (es) 2011-05-20
AU2008312355B2 (en) 2013-07-04
BRPI0818773A2 (pt) 2015-04-14
WO2009052334A1 (en) 2009-04-23
ZA201003520B (en) 2012-07-25
CN101896452A (zh) 2010-11-24
EP2215043B1 (en) 2013-03-06
KR101618068B1 (ko) 2016-05-04
CR11448A (es) 2011-01-14
JP2011500719A (ja) 2011-01-06
IL205046A (en) 2014-09-30

Similar Documents

Publication Publication Date Title
ATE502633T1 (de) Cyclosporins zur behandlung und vorbeugung von augenerkrankungen
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
EA201000950A1 (ru) Азолилметилоксираны, их применение, а также содержащие их средства
EA201270225A1 (ru) СОЕДИНЕНИЯ ДЛЯ УМЕНЬШЕНИЯ ПРОДУКЦИИ β-АМИЛОИДА
EA201190217A1 (ru) Замещенные 2-ацетамидо-5-арил-1,2,4-триазолоны и их применение
MA32811B1 (fr) Nouveaux composés
EA201070158A1 (ru) Сульфонамиды в качестве trpm8 модуляторов
EA200802054A1 (ru) Ингибиторы фермента
EA201071243A1 (ru) Комбинированные композиции для лечения болезни альцгеймера и родственных заболеваний зонизамидом и акампросатом
CY1112083T1 (el) Υποκαθιστουμενα ν-φαινυλο-διπυρρολιδινο καρβοξαμιδια και η θεραπευτικη τους χρηση
DK2212282T3 (da) Substituerede N-phenylbipyrrolidincarboxamider og terapeutisk anvendelse deraf
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
ATE554076T1 (de) Sulfoximinsubstituierte chinazolinderivate als immunmodulatoren, ihre herstellung und ihre verwendung als medikamente
BRPI0415203A (pt) pentanóis reestruturados, um processo para sua produção e seu uso como agentes antiinflamatórios
EA201070496A1 (ru) УГЛЕРОД-СВЯЗАННЫЕ МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ
CR11447A (es) Moduladores de piperidinil y piperazinil de y secretasa
NO20076405L (no) Anvendelse av 24-nor-UDCA
EA201070494A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
BRPI0512732A (pt) formulações tópicas para tratamento de doenças alérgicas
NI201000067A (es) Intermediarios de gsm.
WO2010011626A3 (en) Pyridinyl modulators of ϒ-secretase
EA201070498A1 (ru) МОДУЛЯТОРЫ γ-СЕКРЕТАЗЫ С АМИДНЫМИ СВЯЗЯМИ
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
BRPI0402756A (pt) método para o tratamento de distúrbios cognitivos

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): KZ RU